David Johnson, PhDFounder and CEO at GigaMune
Dr. David S. Johnson is an inventor, entrepreneur, and expert in single-cell genomics. At GigaGen, Dr. Johnson has raised >$63 million from Grifols, Sequoia Capital, NSF, and NIH. In July 2017, GigaGen's T cell work was spun out into a new cellular therapy company, GigaMune, Inc. Dr. Johnson was formerly on the founding team and COO of Natera (NASDAQ: NTRA), where he built a leading CLIA-licensed IVF diagnostics lab in less than a year. Natera had its IPO in July 2015, and sold >$250 million worth of diagnostic tests in 2016. Dr. Johnson earned a Ph.D. in laboratory and computational genomics from Stanford, and has published his work in Science Magazine, Nature Methods, and mAbs.